Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ohio Pediatric Research Association

Neither a doctor nor a teaching hospital

Research payments

$3,677,931

459 payments

Through program year 2025, Ohio Pediatric Research Association is reported as receiving $3,677,931 in research payments, across 459 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $254,922 37
2024 Research $443,510 38
2023 Research $629,919 38
2022 Research $345,486 26
2021 Research $467,066 99
2020 Research $1,053,141 110
2019 Research $483,886 111

Breakdown

Who paid Research payments · program years 2019–2025
  1. Incyte Corporation $1,346,654 214 payments
  2. Merck Sharp & Dohme Corporation $762,518 57 payments
  3. Pfizer Inc. $742,404 66 payments
  4. Sanofi Pasteur Inc. $709,682 73 payments
  5. GlaxoSmithKline, LLC. $115,295 48 payments
  6. AstraZeneca UK Limited $1,378 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $509,202 10 payments
  2. Prevention of Atopic Dermatitis Flare With Treatment of Crisaborole $437,187 18 payments
  3. TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $369,189 78 payments
  4. A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $357,931 14 payments
  5. A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants $229,925 24 payments
  6. PD effects and predictive biomarkers of JAK/STAT inhibition with ruxolitinib in operable head and neck squamous cell carcinoma-a window of opportunity trial $176,727 4 payments
  7. MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $168,050 32 payments
  8. Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. $161,563 4 payments
  9. A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants $154,806 30 payments
  10. Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age. $142,239 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record